# Rewrite chunk 007 — entries 301-350

_Previous: rewrite-PHONE-006.md | Next: rewrite-PHONE-008.md | Index: rewrite-PHONE-INDEX.md_

Edit ONLY the `YOUR REWRITE` section under each entry. The `Original`
block is frozen — do not edit it. Save the file when done. On your
laptop run `python C:\E156\merge-rewrite.py` to assemble a new
workbook (`rewrite-workbook.NEW.txt`) with your edits applied.

---

## Entry 301 ([307/921]) — EvidenceAtlas

<details><summary>Metadata</summary>

```
TITLE: EvidenceAtlas: Cochrane Evidence Network of 501 Interconnected Reviews
TYPE: methods  |  ESTIMAND: Network connectivity and shared-study overlap metrics
DATA: 501 Cochrane reviews with primary study overlap detection
PATH: C:\Models\EvidenceAtlas
```

</details>

### Original (frozen — do not edit)

```
Can a network representation of shared primary studies across Cochrane reviews reveal structural patterns in the evidence ecosystem invisible to individual review examination? EvidenceAtlas builds a review-level network from 501 Cochrane reviews by detecting which primary studies appear in multiple reviews, then annotates nodes with quality, fragility, audit, and oracle-risk metadata. The network merges overlap structure with per-review metrics to create an interactive force-directed graph with 501 nodes and weighted edges representing shared study connections. The resulting network contained 501 nodes with a mean degree of 4.7 connections per review (95% CI 4.1 to 5.3), revealing dense clusters around cardiovascular and oncology therapeutic areas. Hub reviews sharing studies with more than 15 other reviews disproportionately influenced cross-domain evidence propagation and were more likely to carry high fragility indices. Network-level analysis could identify evidence bottlenecks where a small number of primary studies underpin conclusions across many systematic reviews. The network reflects published Cochrane reviews and cannot capture study overlap with non-Cochrane systematic reviews or unpublished analyses.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a network of shared primary studies across Cochrane reviews reveal structural patterns invisible to individual review examination? EvidenceAtlas builds a review-level network from 501 reviews by detecting which studies appear in multiple reviews, then annotates nodes with quality, fragility, and oracle-risk metadata. The network creates an interactive force-directed graph with 501 nodes and weighted edges representing shared study connections. The resulting network had mean degree of 4.7 connections per review (95% CI 4.1 to 5.3), revealing dense clusters around cardiovascular and oncology areas. Hub reviews sharing studies with more than 15 others disproportionately influenced cross-domain evidence propagation and carried higher fragility indices. Network-level analysis could identify evidence bottlenecks where few primary studies underpin conclusions across many reviews. The network reflects published Cochrane reviews and cannot capture overlap with non-Cochrane reviews or unpublished analyses.
<!-- END-REWRITE -->

_Line range 22737-22811 in rewrite-workbook.txt_

---

## Entry 302 ([308/921]) — EvidenceCopula

<details><summary>Metadata</summary>

```
TITLE: EvidenceCopula: Copula-Based Dependence Modelling for Multivariate Meta-Analysis
TYPE: methods  |  ESTIMAND: Joint dependence structure between correlated meta-analytic outcomes
DATA: Bivariate meta-analysis datasets with correlated endpoints
PATH: C:\Models\EvidenceCopula
```

</details>

### Original (frozen — do not edit)

```
Can copula-based dependence modelling capture the joint distribution of correlated meta-analytic outcomes more flexibly than standard bivariate normal assumptions? We built a 342-line dashboard implementing Clayton, Frank, and Gumbel copula families fitted to bivariate meta-analysis data where two outcomes share correlation structure across studies. The tool estimates marginal distributions independently, then fits copula parameters via maximum likelihood to model the dependence structure between outcomes. Clayton copula with theta derived from Kendall tau provided the best fit for asymmetric lower-tail dependence in diagnostic meta-analysis, outperforming bivariate normal by 3.2 AIC units on average. Copula selection via AIC correctly identified the generating family in 89 percent of simulated scenarios (95% CI 84 to 93) across symmetric and asymmetric dependence structures. Copula-based meta-analysis could provide more accurate joint inference for correlated endpoints where the dependence structure is non-elliptical. The approach requires bivariate data from each study and cannot estimate within-study correlations when only marginal summaries are reported.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can copula-based dependence modelling capture joint distributions of correlated meta-analytic outcomes more flexibly than bivariate normal assumptions? We built a 342-line dashboard implementing Clayton, Frank, and Gumbel copula families fitted to bivariate meta-analysis data where outcomes share correlation across studies. The tool estimates marginal distributions independently then fits copula parameters via maximum likelihood to model dependence structure. Clayton copula with theta from Kendall tau provided best fit for asymmetric lower-tail dependence in diagnostic meta-analysis, outperforming bivariate normal by 3.2 AIC units. Copula selection via AIC correctly identified the generating family in 89 percent of simulated scenarios (95% CI 84 to 93). Copula-based meta-analysis could provide more accurate joint inference for correlated endpoints with non-elliptical dependence. The approach requires bivariate study data and cannot estimate within-study correlations from marginal summaries.
<!-- END-REWRITE -->

_Line range 22812-22886 in rewrite-workbook.txt_

---

## Entry 303 ([309/921]) — EvidenceEntropy

<details><summary>Metadata</summary>

```
TITLE: EvidenceEntropy: Information-Theoretic Heterogeneity Assessment for Meta-Analysis
TYPE: methods  |  ESTIMAND: Shannon entropy and mutual information of study-level effects
DATA: Meta-analysis datasets with study-level effect distributions
PATH: C:\Models\EvidenceEntropy
```

</details>

### Original (frozen — do not edit)

```
Can information-theoretic measures provide a more interpretable characterisation of meta-analytic heterogeneity than traditional I-squared and tau-squared statistics? We developed a 390-line dashboard computing Shannon entropy, Kullback-Leibler divergence, and mutual information from discretised study-level effect distributions to quantify the information content and dispersion of meta-analytic evidence bases. The tool bins study effects into equiprobable intervals and computes entropy-based metrics alongside traditional heterogeneity statistics for comparison. Entropy-based heterogeneity showed stronger correlation with prediction interval width (r = 0.91, 95% CI 0.87 to 0.94) than I-squared (r = 0.73) across 200 simulated meta-analyses with varying heterogeneity levels. The mutual information metric between study size and effect magnitude detected small-study effects with sensitivity comparable to Egger regression while being distribution-free. Information-theoretic heterogeneity could complement existing measures by quantifying the predictive uncertainty of the evidence base in natural units. Entropy computation requires discretisation of continuous effect distributions, introducing binning sensitivity that may affect results for meta-analyses with very few studies.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can information-theoretic measures provide more interpretable heterogeneity characterisation than traditional I-squared and tau-squared? We developed a 390-line dashboard computing Shannon entropy, Kullback-Leibler divergence, and mutual information from study-level effect distributions to quantify information content and dispersion. The tool bins study effects into equiprobable intervals and computes entropy metrics alongside traditional heterogeneity statistics. Entropy-based heterogeneity showed stronger correlation with prediction interval width (r = 0.91, 95% CI 0.87 to 0.94) than I-squared (r = 0.73) across 200 simulated meta-analyses. Mutual information between study size and effect magnitude detected small-study effects with sensitivity comparable to Egger regression while being distribution-free. Information-theoretic heterogeneity could complement existing measures by quantifying predictive uncertainty in natural units. Entropy computation requires discretisation introducing binning sensitivity for meta-analyses with very few studies.
<!-- END-REWRITE -->

_Line range 22887-22961 in rewrite-workbook.txt_

---

## Entry 304 ([310/921]) — EvidenceExtremes

<details><summary>Metadata</summary>

```
TITLE: EvidenceExtremes: Extreme Value Analysis for Meta-Analytic Outlier Detection
TYPE: methods  |  ESTIMAND: Generalised extreme value distribution parameters for outlier classification
DATA: Meta-analysis effect size distributions for extreme value modelling
PATH: C:\Models\EvidenceExtremes
```

</details>

### Original (frozen — do not edit)

```
Can extreme value theory provide a principled statistical framework for identifying outlier studies in meta-analysis beyond standard leave-one-out diagnostics? We built a 401-line dashboard fitting generalised extreme value distributions to study-level effect sizes and using the fitted tail behaviour to classify studies as typical, unusual, or extreme outliers. The tool estimates shape, location, and scale parameters of the GEV distribution via maximum likelihood, then computes exceedance probabilities for each study against the fitted tail model. GEV-based outlier detection identified all planted outliers in simulation studies with 94 percent sensitivity (95% CI 90 to 97) while maintaining a 3 percent false positive rate, compared with 78 percent sensitivity for standardised residual thresholds. The shape parameter provided a natural measure of tail heaviness that distinguished between heavy-tailed and light-tailed heterogeneity patterns across clinical domains. Extreme value methods could provide a more theoretically grounded approach to outlier detection than arbitrary residual cutoffs commonly used. The GEV fit requires at least 15 studies for stable parameter estimation and is unreliable for very small meta-analyses.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can extreme value theory provide a principled framework for identifying outlier studies beyond standard leave-one-out diagnostics? We built a 401-line dashboard fitting generalised extreme value distributions to study-level effects and using fitted tail behaviour to classify studies as typical, unusual, or extreme. The tool estimates GEV shape, location, and scale parameters via maximum likelihood then computes exceedance probabilities for each study. GEV-based detection identified all planted outliers with 94 percent sensitivity (95% CI 90 to 97) and 3 percent false positive rate, compared with 78 percent for standardised residual thresholds. The shape parameter provided a natural tail heaviness measure distinguishing heavy-tailed from light-tailed heterogeneity patterns. Extreme value methods could provide more theoretically grounded outlier detection than arbitrary residual cutoffs. The GEV fit requires at least 15 studies for stable estimation and is unreliable for very small meta-analyses.
<!-- END-REWRITE -->

_Line range 22962-23036 in rewrite-workbook.txt_

---

## Entry 305 ([311/921]) — EvidenceKM

<details><summary>Metadata</summary>

```
TITLE: EvidenceKM: Survival of Statistical Significance in Cochrane Meta-Analyses
TYPE: methods  |  ESTIMAND: Median time to loss of statistical significance
DATA: Longitudinal Cochrane meta-analysis update data with significance status tracking
PATH: C:\Models\EvidenceKM
```

</details>

### Original (frozen — do not edit)

```
How long does statistical significance persist in Cochrane meta-analyses, and what is the survival curve for conclusions that are initially significant? We applied Kaplan-Meier survival analysis to track the persistence of statistical significance across sequential Cochrane review updates, treating loss of significance as the event and continued significance as censoring. The dashboard implements log-rank tests for comparing significance survival across clinical domains, heterogeneity levels, and initial sample sizes. Median time to loss of significance was 4.2 years (95% CI 3.5 to 5.1) across meta-analyses that were initially statistically significant. Meta-analyses with high initial heterogeneity (I-squared above 75 percent) had significantly shorter significance survival with median of 2.8 years compared to 6.1 years for low heterogeneity (log-rank p less than 0.001). Significance survival analysis could inform living meta-analysis monitoring intervals and help identify conclusions at highest risk of reversal. The analysis depends on availability of sequential Cochrane updates and cannot account for meta-analyses that were never updated.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How long does statistical significance persist in Cochrane meta-analyses once initially established? We applied Kaplan-Meier analysis to track significance persistence across sequential Cochrane updates, treating loss of significance as the event. The dashboard implements log-rank tests comparing survival across clinical domains, heterogeneity levels, and initial sample sizes. Median time to loss of significance was 4.2 years (95% CI 3.5 to 5.1) across initially significant meta-analyses. High initial heterogeneity (I-squared above 75 percent) showed significantly shorter survival at median 2.8 years versus 6.1 years for low heterogeneity (log-rank p less than 0.001). Significance survival analysis could inform living meta-analysis monitoring intervals and identify conclusions at highest reversal risk. The analysis depends on sequential Cochrane updates and cannot account for meta-analyses never updated.
<!-- END-REWRITE -->

_Line range 23037-23111 in rewrite-workbook.txt_

---

## Entry 306 ([312/921]) — EvidenceMap

<details><summary>Metadata</summary>

```
TITLE: EvidenceMap: Rapid Evidence Gap Map Generator with Bubble-Chart Visualisation
TYPE: methods  |  ESTIMAND: Evidence coverage proportion across intervention-outcome cells
DATA: Systematic review classification data for gap map generation
PATH: C:\Models\EvidenceMap
```

</details>

### Original (frozen — do not edit)

```
Can rapid gap map generation from structured classification data help identify priority research areas more efficiently than manual evidence mapping? We built EvidenceMap as a 2,022-line browser application implementing automated bubble-chart gap map generation from intervention-outcome classification matrices with configurable certainty overlays and study design filtering. The tool accepts CSV classification data and produces interactive gap maps where bubble size encodes study count, colour encodes certainty, and tooltips provide study-level details for each cell. Gap map generation completed in under three seconds for matrices with up to 500 intervention-outcome cells, compared with weeks of manual mapping effort for equivalent scope. Evidence density analysis showed that pharmacological intervention cells contained a median of 12 studies while non-pharmacological cells contained a median of 2 (95% CI 1 to 4). Rapid automated gap mapping could enable living evidence maps that update continuously as new studies are classified. The tool requires pre-classified intervention-outcome data and cannot automatically extract classification from unstructured systematic review text.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can rapid gap map generation from structured classification data identify priority research areas more efficiently than manual mapping? We built EvidenceMap as a 2,022-line browser application implementing automated bubble-chart generation from intervention-outcome matrices with certainty overlays and study design filtering. The tool accepts CSV data producing interactive maps where bubble size encodes study count, colour encodes certainty, and tooltips provide study-level details. Generation completed in under three seconds for matrices with up to 500 cells, compared with weeks of manual effort. Evidence density showed pharmacological cells contained median 12 studies while non-pharmacological cells contained median 2 (95% CI 1 to 4). Rapid automated mapping could enable living evidence maps updating continuously as new studies are classified. The tool requires pre-classified data and cannot extract classification from unstructured review text.
<!-- END-REWRITE -->

_Line range 23112-23186 in rewrite-workbook.txt_

---

## Entry 307 ([313/921]) — EvidenceScore

<details><summary>Metadata</summary>

```
TITLE: EvidenceScore: Composite Evidence Quality Scoring Across Multiple Assessment Dimensions
TYPE: methods  |  ESTIMAND: Composite evidence quality score (0-100)
DATA: Meta-analysis outputs with multi-dimensional quality indicators
PATH: C:\Models\EvidenceScore
```

</details>

### Original (frozen — do not edit)

```
Can a composite score combining statistical robustness, methodological quality, and reporting completeness provide a more comprehensive evidence quality assessment than any single indicator? We developed EvidenceScore implementing weighted aggregation across six quality dimensions: statistical significance and precision, heterogeneity and consistency, publication bias indicators, risk-of-bias profile, GRADE certainty, and fragility index, each scored from zero to one hundred. The composite algorithm applies configurable dimension weights with default equal weighting and generates an overall evidence quality score with dimension-level breakdown and radar chart visualisation. Composite scores showed strong discrimination between meta-analyses classified as high versus low quality by expert panels, with AUC of 0.88 (95% CI 0.83 to 0.92) for the default weighting scheme. Sensitivity analysis across alternative weighting schemes showed composite scores varied by less than 8 points on the hundred-point scale, suggesting robustness to weight specification. Multi-dimensional evidence scoring could supplement single-metric assessments in rapid evidence triage and systematic review prioritisation. The composite weights are heuristic and the score should not be interpreted as a validated measure of evidence trustworthiness.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a composite score combining statistical robustness, methodological quality, and reporting completeness provide more comprehensive assessment than any single indicator? We developed EvidenceScore implementing weighted aggregation across six dimensions: significance and precision, heterogeneity, publication bias, risk-of-bias, GRADE certainty, and fragility index scored from zero to one hundred. The algorithm applies configurable weights with default equal weighting generating an overall score with dimension breakdown and radar visualisation. Composite scores showed strong discrimination between expert-classified high versus low quality meta-analyses with AUC of 0.88 (95% CI 0.83 to 0.92). Sensitivity analysis showed scores varied by less than 8 points across alternative weighting schemes suggesting robustness to specification. Multi-dimensional scoring could supplement single-metric assessments in rapid evidence triage. The composite weights are heuristic and should not be interpreted as validated trustworthiness measures.
<!-- END-REWRITE -->

_Line range 23187-23261 in rewrite-workbook.txt_

---

## Entry 308 ([314/921]) — EvidenceSpectral

<details><summary>Metadata</summary>

```
TITLE: EvidenceSpectral: Spectral Analysis of Meta-Analytic Heterogeneity Patterns
TYPE: methods  |  ESTIMAND: Spectral decomposition of between-study variance
DATA: Meta-analysis datasets for frequency-domain heterogeneity analysis
PATH: C:\Models\EvidenceSpectral
```

</details>

### Original (frozen — do not edit)

```
Can spectral decomposition of study-level effects reveal periodic or structured patterns in meta-analytic heterogeneity that standard statistics miss? We built a 551-line dashboard applying discrete Fourier transform to chronologically ordered study effects to detect temporal periodicity, trend components, and noise structure in the between-study variance. The tool computes power spectral density, identifies dominant frequencies, and decomposes total heterogeneity into trend, periodic, and random components. Spectral analysis detected significant periodic components in 12 percent of tested meta-analyses (95% CI 8 to 17), suggesting temporal patterns in treatment effects related to changes in clinical practice or patient populations. The trend component accounted for more than 30 percent of total heterogeneity in 23 percent of meta-analyses, indicating systematic temporal drift in treatment effects. Spectral heterogeneity analysis could alert meta-analysts to non-stationary evidence patterns where pooling assumes exchangeability that may not hold temporally. The method requires chronological ordering and at least 20 studies for reliable spectral estimation.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can spectral decomposition reveal periodic or structured patterns in meta-analytic heterogeneity that standard statistics miss? We built a 551-line dashboard applying discrete Fourier transform to chronologically ordered study effects to detect temporal periodicity, trend, and noise structure. The tool computes power spectral density, identifies dominant frequencies, and decomposes heterogeneity into trend, periodic, and random components. Spectral analysis detected significant periodic components in 12 percent of tested meta-analyses (95% CI 8 to 17) suggesting temporal patterns related to practice changes. The trend component accounted for more than 30 percent of total heterogeneity in 23 percent of analyses indicating systematic temporal drift. Spectral analysis could alert meta-analysts to non-stationary evidence where pooling assumes exchangeability not holding temporally. The method requires chronological ordering and at least 20 studies for reliable estimation.
<!-- END-REWRITE -->

_Line range 23262-23336 in rewrite-workbook.txt_

---

## Entry 309 ([315/921]) — EvidenceTopology

<details><summary>Metadata</summary>

```
TITLE: EvidenceTopology: Topological Data Analysis for Meta-Analytic Clustering
TYPE: methods  |  ESTIMAND: Persistent homology features and Betti numbers
DATA: Multivariate study-level features from meta-analysis datasets
PATH: C:\Models\EvidenceTopology
```

</details>

### Original (frozen — do not edit)

```
Can topological data analysis reveal hidden clustering and structural features in meta-analytic evidence that traditional forest plots and heterogeneity statistics cannot detect? We built a 463-line dashboard applying persistent homology to multivariate study-level features including effect size, sample size, risk-of-bias, and publication year to identify topological features in the evidence landscape. The tool computes Vietoris-Rips complexes, tracks birth and death of topological features across filtration scales, and visualises persistence diagrams and barcodes alongside traditional forest plots. Persistent homology identified distinct study clusters in 34 percent of tested meta-analyses (95% CI 28 to 41) that were not detectable by subgroup analysis on any single covariate. The number of persistent connected components (Betti-0) correlated with the number of distinct study populations contributing to the meta-analysis more strongly than I-squared. Topological analysis could complement traditional heterogeneity assessment by revealing multi-dimensional structure in the evidence base. The method is computationally intensive for meta-analyses with more than 100 studies and topological features require domain expertise for clinical interpretation.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can topological data analysis reveal hidden clustering that forest plots and heterogeneity statistics cannot detect? We built a 463-line dashboard applying persistent homology to multivariate study features including effect size, sample size, risk-of-bias, and publication year. The tool computes Vietoris-Rips complexes, tracks birth and death of features across filtration scales, and visualises persistence diagrams alongside forest plots. Persistent homology identified distinct clusters in 34 percent of tested meta-analyses (95% CI 28 to 41) not detectable by single-covariate subgroup analysis. Persistent connected components correlated with distinct study populations more strongly than I-squared. Topological analysis could complement heterogeneity assessment by revealing multi-dimensional evidence structure. The method is computationally intensive beyond 100 studies and features require domain expertise for interpretation.
<!-- END-REWRITE -->

_Line range 23337-23411 in rewrite-workbook.txt_

---

## Entry 310 ([316/921]) — HyperMeta

<details><summary>Metadata</summary>

```
TITLE: HyperMeta: Evidence Geometry Engine with Seven Mathematical Modules
TYPE: methods  |  ESTIMAND: Geometric and topological properties of meta-analytic evidence spaces
DATA: Meta-analysis datasets projected into hyperbolic and Riemannian spaces
PATH: C:\Models\HyperMeta
```

</details>

### Original (frozen — do not edit)

```
Can projecting meta-analytic evidence into non-Euclidean geometric spaces reveal structural properties invisible in standard statistical summaries? We built HyperMeta as a 1,809-line browser application implementing seven mathematical modules: hyperbolic embedding, Riemannian curvature estimation, geodesic distance computation, parallel transport of confidence intervals, Voronoi tessellation in evidence space, persistent homology, and information geometry metrics. Each module operates on study-level multivariate features projected into the appropriate geometric space, with interactive visualisation of the resulting structures. Hyperbolic embedding preserved hierarchical relationships between studies with 15 percent lower distortion (95% CI 11 to 19) than Euclidean multidimensional scaling across test meta-analyses. Riemannian curvature of the evidence manifold correlated with traditional heterogeneity measures but additionally captured directional variation that I-squared cannot represent. Geometric analysis could provide a richer characterisation of evidence structure for meta-analyses where standard statistics underrepresent the complexity of between-study variation. The mathematical framework requires familiarity with differential geometry concepts that may limit accessibility for clinical researchers without quantitative training.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can projecting meta-analytic evidence into non-Euclidean spaces reveal properties invisible in standard summaries? We built HyperMeta as a 1,809-line application implementing seven modules: hyperbolic embedding, Riemannian curvature, geodesic distance, parallel transport, Voronoi tessellation, persistent homology, and information geometry. Each module operates on study-level features projected into the appropriate geometric space with interactive visualisation. Hyperbolic embedding preserved hierarchical relationships with 15 percent lower distortion (95% CI 11 to 19) than Euclidean multidimensional scaling. Riemannian curvature correlated with traditional heterogeneity but additionally captured directional variation I-squared cannot represent. Geometric analysis could provide richer characterisation of evidence structure where standard statistics underrepresent between-study variation. The framework requires differential geometry familiarity that may limit accessibility for clinical researchers.
<!-- END-REWRITE -->

_Line range 23412-23486 in rewrite-workbook.txt_

---

## Entry 311 ([317/921]) — InfoGeoMA

<details><summary>Metadata</summary>

```
TITLE: InfoGeoMA: Information-Geometric Meta-Analysis on Statistical Manifolds
TYPE: methods  |  ESTIMAND: Fisher information distance between study-level distributions
DATA: Meta-analysis datasets for information-geometric distance computation
PATH: C:\Models\InfoGeoMA
```

</details>

### Original (frozen — do not edit)

```
Can information geometry provide a natural metric for measuring distances between studies in meta-analysis that respects the curvature of the underlying statistical model? We built InfoGeoMA as a 586-line browser application computing Fisher information distances, geodesics on statistical manifolds, and natural gradient heterogeneity measures for normal-normal and binomial meta-analysis models. The tool estimates the Fisher information matrix at each study point, computes geodesic distances between studies on the statistical manifold, and uses these distances for outlier detection and clustering. Fisher information distance correctly identified outlier studies with 91 percent sensitivity (95% CI 86 to 95) compared with 82 percent for Mahalanobis distance, by accounting for the curvature of the parameter space. Natural gradient heterogeneity measures showed stronger monotonic relationship with prediction interval coverage than I-squared across simulation scenarios. Information-geometric methods could improve meta-analytic inference by using distances that reflect the natural geometry of statistical models. The approach requires specification of the parametric family and may not apply to non-parametric or distribution-free meta-analysis methods.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can information geometry provide a natural distance metric between studies respecting the curvature of the statistical model? We built InfoGeoMA as a 586-line application computing Fisher information distances, manifold geodesics, and natural gradient heterogeneity for normal-normal and binomial models. The tool estimates Fisher information at each study point, computes geodesic distances, and uses these for outlier detection and clustering. Fisher distance identified outliers with 91 percent sensitivity (95% CI 86 to 95) versus 82 percent for Mahalanobis distance by accounting for parameter space curvature. Natural gradient heterogeneity showed stronger monotonic relationship with prediction interval coverage than I-squared. Information-geometric methods could improve inference by using distances reflecting natural statistical model geometry. The approach requires parametric family specification and may not apply to non-parametric methods.
<!-- END-REWRITE -->

_Line range 23487-23561 in rewrite-workbook.txt_

---

## Entry 312 ([318/921]) — Integrity-Guard-Forensics

<details><summary>Metadata</summary>

```
TITLE: Integrity Guard Forensics: Automated Quality Assurance for Clinical Trial Reporting
TYPE: methods  |  ESTIMAND: Reporting integrity score per trial
DATA: ClinicalTrials.gov trial records for automated integrity screening
PATH: C:\Integrity-Guard-Forensics
```

</details>

### Original (frozen — do not edit)

```
Can automated forensic screening of ClinicalTrials.gov records detect reporting integrity issues that would otherwise require manual auditor review? We developed Integrity Guard implementing statistical forensic methods including Benford digit analysis, GRIM granularity testing, terminal digit distribution assessment, and cross-field consistency checks applied to structured trial registry data. The tool processes individual trial records and generates integrity reports with per-field risk scores, flagged anomalies, and composite integrity ratings from clean through suspicious to flagged. Automated screening detected planted integrity anomalies with 89 percent sensitivity (95% CI 84 to 93) and 94 percent specificity across a validation set of clean and manipulated registry records. Cross-field consistency checks identified enrollment numbers incompatible with reported outcome denominators in 7 percent of screened records, suggesting data entry errors or post-hoc sample modifications. Automated integrity screening could serve as a first-pass quality gate for systematic reviewers assessing registry records before inclusion in meta-analyses. The tool screens registry metadata and cannot detect manipulation of individual patient data or selective outcome reporting within published manuscripts.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can automated forensic screening of ClinicalTrials.gov records detect reporting integrity issues requiring manual review? We developed Integrity Guard implementing Benford analysis, GRIM testing, terminal digit assessment, and cross-field consistency checks applied to structured registry data. The tool processes trial records generating integrity reports with per-field risk scores, flagged anomalies, and composite ratings. Automated screening detected planted anomalies with 89 percent sensitivity (95% CI 84 to 93) and 94 percent specificity across validation records. Cross-field checks identified enrollment incompatible with outcome denominators in 7 percent of records, suggesting data entry errors or post-hoc modifications. Automated screening could serve as a first-pass quality gate for reviewers assessing registry records. The tool screens metadata and cannot detect individual patient data manipulation or selective outcome reporting.
<!-- END-REWRITE -->

_Line range 23562-23636 in rewrite-workbook.txt_

---

## Entry 313 ([319/921]) — MetaFrontierLab

<details><summary>Metadata</summary>

```
TITLE: MetaFrontierLab: Prototype Meta-Analysis Framework for Frontier Methods Development
TYPE: methods  |  ESTIMAND: Framework extensibility and method integration coverage
DATA: Prototype implementations of frontier meta-analysis methods
PATH: C:\MetaFrontierLab
```

</details>

### Original (frozen — do not edit)

```
Can a modular prototype framework accelerate development and testing of frontier meta-analysis methods by providing standardised interfaces and validation infrastructure? We developed MetaFrontierLab as a prototype meta-analysis framework implementing pluggable method modules, standardised data schemas, automated validation against R reference packages, and benchmark dataset management for rapid method prototyping. The framework provides a common interface for effect size computation, heterogeneity estimation, confidence interval construction, and diagnostic output generation that new methods can implement to gain immediate access to validation and benchmarking infrastructure. New method modules were integrated in median 45 minutes compared with estimated 8 hours for standalone implementation, representing a 90 percent reduction in development overhead. Validation against R metafor reference outputs achieved exact numerical agreement within four decimal places for all implemented standard methods. A modular prototyping framework could reduce the barrier to implementing and testing novel meta-analysis methods by providing reusable infrastructure. The prototype supports normal-normal models and requires extension for binary, survival, and diagnostic test accuracy data types.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a modular prototype framework accelerate development of frontier meta-analysis methods with standardised interfaces and validation? We developed MetaFrontierLab implementing pluggable method modules, standardised schemas, automated R reference validation, and benchmark management for rapid prototyping. The framework provides common interfaces for effect size computation, heterogeneity estimation, confidence intervals, and diagnostics that new methods implement to access validation infrastructure. New modules integrated in median 45 minutes versus estimated 8 hours standalone, representing 90 percent development overhead reduction. Validation against R metafor achieved numerical agreement within four decimal places for all standard methods. A modular framework could reduce barriers to implementing novel meta-analysis methods by providing reusable infrastructure. The prototype supports normal-normal models and requires extension for binary, survival, and DTA data types.
<!-- END-REWRITE -->

_Line range 23637-23711 in rewrite-workbook.txt_

---

## Entry 314 ([320/921]) — MetaVoI

<details><summary>Metadata</summary>

```
TITLE: MetaVoI: Value of Information Analysis from Meta-Analysis Output
TYPE: methods  |  ESTIMAND: Expected value of perfect and partial information (EVPI/EVPPI)
DATA: Meta-analysis results with decision thresholds for VoI computation
PATH: C:\Models\MetaVoI
```

</details>

### Original (frozen — do not edit)

```
Can Value of Information analysis computed directly from meta-analysis output quantify whether funding another trial is worthwhile given existing evidence? We built MetaVoI as a browser tool implementing expected value of perfect information, expected value of partial perfect information, and expected value of sample information calculations from pooled meta-analysis estimates and their uncertainty distributions. The tool accepts the pooled effect, standard error, heterogeneity variance, and a clinical decision threshold to compute the population-level value of resolving remaining uncertainty. For a cardiovascular example with moderate heterogeneity, EVPI was 2.3 million quality-adjusted life-years (95% CI 1.8 to 2.9 million) at a willingness-to-pay threshold of 30,000 per QALY. EVSI analysis showed that the next trial would need to enrol at least 4,000 patients to capture more than 50 percent of the remaining information value. Decision-theoretic VoI from meta-analysis could directly inform research priority-setting and trial design by quantifying the expected benefit of additional evidence. The analysis assumes a specific decision model structure and willingness-to-pay threshold that may not reflect all stakeholder perspectives.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can Value of Information analysis from meta-analysis output quantify whether funding another trial is worthwhile? We built MetaVoI implementing EVPI, EVPPI, and EVSI calculations from pooled estimates, standard error, heterogeneity, and clinical decision thresholds. The tool computes population-level value of resolving remaining uncertainty given current evidence precision. For a cardiovascular example with moderate heterogeneity, EVPI was 2.3 million QALYs (95% CI 1.8 to 2.9 million) at 30,000 per QALY willingness-to-pay. EVSI showed the next trial would need 4,000 patients to capture more than 50 percent of remaining information value. Decision-theoretic VoI could directly inform research priority-setting by quantifying expected benefit of additional evidence. The analysis assumes specific decision model structure and willingness-to-pay thresholds that may not reflect all perspectives.
<!-- END-REWRITE -->

_Line range 23712-23786 in rewrite-workbook.txt_

---

## Entry 315 ([321/921]) — MoneyTrail

<details><summary>Metadata</summary>

```
TITLE: MoneyTrail: Financial Conflict of Interest Detection in Clinical Trial Networks
TYPE: methods  |  ESTIMAND: Funding bias effect modification on pooled treatment estimates
DATA: Trial-level funding source data linked to meta-analysis outcomes
PATH: C:\Models\MoneyTrail
```

</details>

### Original (frozen — do not edit)

```
Does industry funding systematically modify treatment effect estimates in meta-analyses, and can funding source be incorporated as an effect modifier in routine evidence synthesis? We developed MoneyTrail implementing funding-stratified meta-analysis with interaction tests, bias-adjusted pooling that down-weights industry-funded studies, and network visualisation of financial relationships between sponsors and trial investigators. The tool classifies studies by funding source and computes within-stratum pooled effects, funding-by-treatment interaction p-values, and adjusted estimates using empirical bias priors from meta-epidemiological data. Industry-funded studies showed treatment effects 0.13 standard deviations larger (95% CI 0.08 to 0.18) than independently funded studies across the validation meta-analysis corpus, consistent with published meta-epidemiological estimates. Bias-adjusted pooling shifted 18 percent of meta-analytic conclusions from significant to non-significant when industry funding was the dominant evidence source. Routine funding-source adjustment could improve the accuracy of meta-analytic conclusions in therapeutic areas dominated by industry-sponsored trials. The approach assumes funding source is accurately reported and uses aggregate bias estimates that may not reflect funding effects in specific therapeutic areas.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Does industry funding systematically modify treatment effect estimates, and can it be incorporated as an effect modifier? We developed MoneyTrail implementing funding-stratified meta-analysis with interaction tests, bias-adjusted pooling, and network visualisation of financial relationships between sponsors and investigators. The tool classifies studies by funding source, computes within-stratum effects, interaction p-values, and adjusted estimates using empirical bias priors. Industry-funded studies showed effects 0.13 standard deviations larger (95% CI 0.08 to 0.18) than independently funded studies across the validation corpus. Bias-adjusted pooling shifted 18 percent of conclusions from significant to non-significant when industry funding dominated the evidence. Routine funding-source adjustment could improve meta-analytic accuracy in areas dominated by industry-sponsored trials. The approach assumes accurate funding reporting and uses aggregate bias estimates that may not reflect specific therapeutic areas.
<!-- END-REWRITE -->

_Line range 23787-23861 in rewrite-workbook.txt_

---

## Entry 316 ([322/921]) — PatientMA

<details><summary>Metadata</summary>

```
TITLE: PatientMA: Patient-Centred Meta-Analysis with OutcomeGap, TrialFit, and CardioEvidence Pilots
TYPE: methods  |  ESTIMAND: Patient-relevance score and outcome gap index
DATA: Cochrane reviews mapped to patient-important outcomes and trial design features
PATH: C:\Models\PatientMA
```

</details>

### Original (frozen — do not edit)

```
How well do current meta-analyses address the outcomes that matter most to patients, and can patient-centred metrics quantify the gap between what trials measure and what patients value? We developed PatientMA as a three-pilot suite implementing OutcomeGap scoring of patient-relevance for meta-analytic endpoints, TrialFit assessment of trial design alignment with real-world patient populations, and CardioEvidence integration of both perspectives for cardiovascular evidence synthesis. The tools map trial outcomes to a patient-importance taxonomy and compute gap indices measuring the distance between measured and valued outcomes. Across 93 validated test cases the outcome gap index correctly identified meta-analyses measuring surrogate endpoints as having lower patient-relevance scores than those measuring patient-important outcomes. TrialFit assessment showed that 42 percent of cardiovascular trial populations had significant demographic mismatches with the target clinical population based on age, sex, and comorbidity profile comparisons. Patient-centred meta-analysis could shift evidence synthesis from averaging treatment effects to evaluating whether the evidence answers the questions patients actually ask. The patient-importance taxonomy relies on published preference elicitation data and may not capture individual patient priorities.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How well do current meta-analyses address outcomes patients value most? We developed PatientMA as a three-pilot suite: OutcomeGap scoring patient-relevance, TrialFit assessing trial-population alignment, and CardioEvidence integrating both for cardiovascular synthesis. The tools map trial outcomes to a patient-importance taxonomy and compute gap indices measuring distance between measured and valued outcomes. Across 93 test cases the gap index correctly identified surrogate-endpoint meta-analyses as having lower patient-relevance than those measuring patient-important outcomes. TrialFit showed 42 percent of cardiovascular trial populations had significant demographic mismatches with target clinical populations. Patient-centred meta-analysis could shift synthesis from averaging effects to evaluating whether evidence answers questions patients ask. The importance taxonomy relies on published preference data and may not capture individual priorities.
<!-- END-REWRITE -->

_Line range 23862-23936 in rewrite-workbook.txt_

---

## Entry 317 ([323/921]) — PriorLab

<details><summary>Metadata</summary>

```
TITLE: PriorLab: Interactive Bayesian Prior Elicitation Using SHELF Methods
TYPE: methods  |  ESTIMAND: Elicited prior distribution parameters (mean, variance, shape)
DATA: Expert-elicited quantile judgments for Bayesian prior specification
PATH: C:\Models\PriorLab
```

</details>

### Original (frozen — do not edit)

```
Can interactive browser-based prior elicitation using the SHELF framework make Bayesian meta-analysis priors more transparent and reproducible than default weakly informative choices? We built PriorLab implementing the Sheffield Elicitation Framework methods including roulette, histogram, quartile, and tertile elicitation interfaces for specifying expert beliefs about treatment effects. The tool fits normal, log-normal, beta, and gamma distributions to elicited quantiles using least-squares matching and displays the resulting prior alongside the data likelihood and posterior in real time. Elicited priors produced posterior estimates within 0.05 standard deviations of the known truth (95% CI 0.02 to 0.08) in simulation scenarios where expert knowledge was accurately calibrated. Sensitivity analysis comparing elicited priors against default vague priors showed that informative elicitation reduced posterior variance by 35 percent on average when expert beliefs were well-calibrated. Transparent prior elicitation could improve the credibility of Bayesian meta-analysis by making the prior specification process auditable and reproducible. The quality of elicited priors depends entirely on expert calibration and poorly calibrated beliefs can worsen posterior accuracy.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can interactive prior elicitation using SHELF make Bayesian meta-analysis priors more transparent than default weakly informative choices? We built PriorLab implementing Sheffield Elicitation Framework methods including roulette, histogram, quartile, and tertile interfaces for specifying expert beliefs about treatment effects. The tool fits normal, log-normal, beta, and gamma distributions to elicited quantiles using least-squares matching and displays prior alongside likelihood and posterior in real time. Elicited priors produced posteriors within 0.05 standard deviations of truth (95% CI 0.02 to 0.08) when expert knowledge was accurately calibrated. Sensitivity analysis showed informative elicitation reduced posterior variance by 35 percent compared to vague priors when beliefs were well-calibrated. Transparent elicitation could improve Bayesian meta-analysis credibility by making prior specification auditable and reproducible. Prior quality depends entirely on expert calibration and poorly calibrated beliefs can worsen posterior accuracy.
<!-- END-REWRITE -->

_Line range 23937-24011 in rewrite-workbook.txt_

---

## Entry 318 ([324/921]) — QualSynth

<details><summary>Metadata</summary>

```
TITLE: QualSynth: Browser-Based Qualitative Evidence Synthesis with Meta-Ethnography and CERQual
TYPE: methods  |  ESTIMAND: CERQual confidence assessment for qualitative findings
DATA: Qualitative study data for thematic synthesis and meta-ethnography
PATH: C:\Models\QualSynth
```

</details>

### Original (frozen — do not edit)

```
Can qualitative evidence synthesis methods be implemented in a browser tool to make meta-ethnography and thematic synthesis accessible without specialised qualitative software? We built QualSynth implementing Noblit and Hare meta-ethnography, Thomas and Harden thematic synthesis, and CERQual confidence assessment for qualitative findings in an interactive browser application. The tool supports study coding, theme development, reciprocal translation, refutational synthesis, and lines-of-argument synthesis with structured CERQual assessment across four domains. Theme saturation analysis showed that new themes ceased emerging after coding 75 percent of included studies across three test datasets, consistent with published qualitative saturation benchmarks. CERQual assessments produced confidence ratings from very low to high with domain-level justifications traceable to contributing study data. Browser-based qualitative synthesis could lower the barrier to rigorous qualitative evidence synthesis for mixed-methods review teams. The tool provides structured workflow support but cannot replace the interpretive judgment required for qualitative analysis.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can qualitative evidence synthesis be implemented in a browser to make meta-ethnography accessible without specialised software? We built QualSynth implementing Noblit and Hare meta-ethnography, Thomas and Harden thematic synthesis, and CERQual confidence assessment in an interactive browser application. The tool supports study coding, theme development, reciprocal translation, refutational synthesis, and structured CERQual assessment across four domains. Theme saturation analysis showed new themes ceased emerging after coding 75 percent of studies across three test datasets, consistent with published benchmarks. CERQual produced confidence ratings from very low to high with domain justifications traceable to contributing study data. Browser-based qualitative synthesis could lower barriers for mixed-methods review teams. The tool provides structured workflow but cannot replace interpretive judgment required for qualitative analysis.
<!-- END-REWRITE -->

_Line range 24012-24086 in rewrite-workbook.txt_

---

## Entry 319 ([325/921]) — SROCPlotter

<details><summary>Metadata</summary>

```
TITLE: SROCPlotter: Summary Receiver Operating Characteristic Curve Generator
TYPE: methods  |  ESTIMAND: Summary sensitivity and specificity with SROC curve AUC
DATA: Diagnostic test accuracy study data (2x2 tables)
PATH: C:\Models\SROCPlotter
```

</details>

### Original (frozen — do not edit)

```
Can a lightweight browser tool generate publication-quality SROC curves from diagnostic test accuracy data with bivariate model fitting? We built SROCPlotter as a minimal 32-line redirect application linking to the full DTA meta-analysis tools that implement bivariate random-effects models for summary sensitivity and specificity estimation with SROC curve generation. The tool computes the bivariate normal model parameters, plots the SROC curve with confidence and prediction regions, and exports the resulting figure in SVG format. Summary operating points matched R mada package output within three decimal places for all validation datasets including imaging, biomarker, and clinical assessment diagnostic studies. The SROC curve with hierarchical confidence region provided correct coverage in 94 percent of simulated datasets with known diagnostic accuracy parameters. Accessible SROC generation could support diagnostic test accuracy systematic reviews where graphical presentation is essential for clinical interpretation. The bivariate model assumes normally distributed logit-transformed sensitivities and specificities which may not hold for studies with very low or very high accuracy.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a lightweight browser tool generate publication-quality SROC curves with bivariate model fitting? SROCPlotter links to full DTA meta-analysis tools implementing bivariate random-effects models for summary sensitivity and specificity estimation with SROC generation. The tool computes bivariate normal parameters, plots the SROC curve with confidence and prediction regions, and exports SVG figures. Summary operating points matched R mada output within three decimal places for all validation datasets including imaging, biomarker, and clinical assessment studies. The SROC curve with hierarchical confidence region provided correct coverage in 94 percent of simulated datasets. Accessible SROC generation could support DTA systematic reviews where graphical output is necessary. The bivariate model assumes normality of logit-transformed accuracies which may not hold at extreme values.
<!-- END-REWRITE -->

_Line range 24087-24161 in rewrite-workbook.txt_

---

## Entry 320 ([326/921]) — SafeMA

<details><summary>Metadata</summary>

```
TITLE: SafeMA: Anytime-Valid Sequential Meta-Analysis with E-Values
TYPE: methods  |  ESTIMAND: E-value and anytime-valid confidence sequence
DATA: Sequential meta-analysis data for anytime-valid inference
PATH: C:\Models\SafeMA
```

</details>

### Original (frozen — do not edit)

```
Can e-value-based sequential testing provide anytime-valid meta-analytic inference that controls type I error regardless of the data-dependent stopping rule? We built SafeMA as an 814-line browser application implementing e-value computation, anytime-valid confidence sequences, and growth-rate optimal e-processes for sequential random-effects meta-analysis. The tool computes product e-values at each study addition, constructs confidence sequences that maintain coverage at any stopping time, and visualises the cumulative evidence trajectory alongside traditional monitoring boundaries. Anytime-valid confidence sequences maintained nominal 95 percent coverage in 97 percent of simulated sequential analyses (95% CI 95 to 99) compared with 82 percent for traditional confidence intervals applied sequentially. The e-value crossed the rejection threshold at median of 1.3 additional studies beyond the point where traditional sequential analysis would stop, reflecting the conservative cost of anytime-validity. E-value-based meta-analysis could provide valid inference for living meta-analyses where the timing and frequency of evidence updates cannot be pre-specified. The approach requires specification of a mixing distribution and may have lower power than pre-planned group-sequential designs when the analysis schedule is fixed.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can e-value-based sequential testing provide anytime-valid meta-analytic inference controlling type I error regardless of stopping rule? We built SafeMA as an 814-line application implementing e-value computation, anytime-valid confidence sequences, and growth-rate optimal e-processes for sequential random-effects meta-analysis. The tool computes product e-values at each study addition and constructs confidence sequences maintaining coverage at any stopping time. Anytime-valid sequences maintained 95 percent coverage in 97 percent of simulated analyses (95% CI 95 to 99) versus 82 percent for traditional intervals applied sequentially. The e-value crossed rejection threshold at median 1.3 additional studies beyond traditional stopping, reflecting the cost of anytime-validity. E-value meta-analysis could provide valid inference for living meta-analyses where update timing cannot be pre-specified. The approach requires mixing distribution specification and may have lower power than pre-planned designs with fixed schedules.
<!-- END-REWRITE -->

_Line range 24162-24236 in rewrite-workbook.txt_

---

## Entry 321 ([327/921]) — TherapyGraveyard

<details><summary>Metadata</summary>

```
TITLE: TherapyGraveyard: Cardiovascular Drug and Technique Attrition Map
TYPE: clinical  |  ESTIMAND: Attrition rate and time-to-abandonment by therapeutic class
DATA: 581 cardiovascular interventions tracked from introduction through abandonment or survival
PATH: C:\Models\TherapyGraveyard
```

</details>

### Original (frozen — do not edit)

```
What is the historical attrition rate for cardiovascular drugs and surgical techniques, and which intervention characteristics predict eventual abandonment? We constructed a 1,322-line interactive attrition map tracking 581 cardiovascular interventions from their introduction through adoption, maturation, decline, and abandonment or survival. The map classifies each intervention by therapeutic class, mechanism, era of introduction, evidence base strength at peak adoption, and reason for decline using structured coding from regulatory actions, guideline changes, and trial results. Overall cardiovascular therapy attrition was 34 percent (95% CI 30 to 38) with median time-to-abandonment of 18 years for drugs that ultimately failed. Anti-arrhythmic agents had the highest class-level attrition at 52 percent, driven primarily by safety signals emerging after widespread adoption based on surrogate endpoint evidence. Historical attrition patterns could inform prospective assessment of which current therapies face the highest risk of future evidence reversal. The map relies on published literature and regulatory records and cannot capture therapies that were quietly abandoned without formal withdrawal or guideline update.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What is the historical attrition rate for cardiovascular drugs and techniques, and what predicts abandonment? We constructed a 1,322-line attrition map tracking 581 interventions from introduction through adoption, decline, and abandonment or persistence. The map classifies each by therapeutic class, mechanism, era, evidence strength at peak adoption, and decline reason from regulatory actions, guidelines, and trials. Overall cardiovascular therapy attrition was 34 percent (95% CI 30 to 38) with median time-to-abandonment of 18 years. Anti-arrhythmic agents had highest class attrition at 52 percent, driven by safety signals after adoption based on surrogate endpoint evidence. Historical attrition patterns could inform prospective assessment of which therapies face highest reversal risk. The map relies on published literature and cannot capture therapies quietly abandoned without formal withdrawal.
<!-- END-REWRITE -->

_Line range 24237-24311 in rewrite-workbook.txt_

---

## Entry 322 ([328/921]) — TransportMA

<details><summary>Metadata</summary>

```
TITLE: TransportMA: Causal Transportability Meta-Analysis for External Validity Assessment
TYPE: methods  |  ESTIMAND: Transportability-adjusted treatment effect
DATA: Trial and target population data for causal transportability estimation
PATH: C:\Models\TransportMA
```

</details>

### Original (frozen — do not edit)

```
Can causal transportability methods be integrated into meta-analysis to formally adjust pooled treatment effects for differences between trial populations and target clinical populations? We built TransportMA as a 587-line browser application implementing inverse odds of selection weighting, calibration weighting, and doubly robust transportability estimation within the meta-analytic framework. The tool accepts trial-level covariate summaries and target population characteristics to compute transportability-adjusted effect estimates with appropriate variance estimation. Transportability adjustment shifted pooled estimates by a median of 0.09 standard deviations (95% CI 0.04 to 0.15) across test scenarios with moderate covariate shift between trial and target populations. The doubly robust estimator maintained bias below 0.02 standard deviations even when either the outcome model or the selection model was misspecified. Transportability-adjusted meta-analysis could improve the external validity of pooled estimates by formally accounting for population differences rather than assuming exchangeability. The method requires covariate-level data from both trial and target populations which is often unavailable for published meta-analyses relying solely on aggregate results.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can causal transportability methods adjust pooled effects for differences between trial and target populations? We built TransportMA as a 587-line application implementing inverse odds weighting, calibration weighting, and doubly robust transportability estimation within meta-analysis. The tool accepts trial-level covariate summaries and target population characteristics for adjusted estimates with appropriate variance. Adjustment shifted pooled estimates by median 0.09 standard deviations (95% CI 0.04 to 0.15) across scenarios with moderate covariate shift. The doubly robust estimator maintained bias below 0.02 even when either outcome or selection model was misspecified. Transportability-adjusted meta-analysis could improve external validity by formally accounting for population differences. The method requires covariate data from both populations often unavailable for aggregate-only published meta-analyses.
<!-- END-REWRITE -->

_Line range 24312-24386 in rewrite-workbook.txt_

---

## Entry 323 ([329/921]) — TrustGate

<details><summary>Metadata</summary>

```
TITLE: TrustGate: Trust-Weighted Meta-Meta-Analysis with Evidence Erosion Detection
TYPE: methods  |  ESTIMAND: Trust-adjusted pooled estimate and evidence erosion rate
DATA: Multi-review evidence collections with quality, fragility, and bias metadata
PATH: C:\Models\TrustGate
```

</details>

### Original (frozen — do not edit)

```
Can trust-weighted meta-meta-analysis quantify how much evidence erosion affects the reliability of systematic review conclusions when quality, fragility, and bias indicators are jointly considered? We developed TrustGate as a browser tool implementing trust-weighted pooling across multiple meta-analyses where each review receives a composite trust score based on fragility index, GRADE certainty, publication bias indicators, and study overlap metrics. The trust gate applies multiplicative down-weighting to low-trust reviews before meta-meta-analytic pooling, producing trust-adjusted estimates and erosion diagnostics. Across 104 review collections the trust-adjusted estimate diverged from the naive pooled estimate by a median of 0.12 standard deviations (95% CI 0.08 to 0.17), with 63.9 percent showing evidence of meaningful trust erosion. Red flag analysis identified 104 specific quality concerns across the review collections with the most common being fragility index below 3 and prediction intervals crossing the null. Trust-weighted meta-meta-analysis could provide a quality-adjusted synthesis when multiple systematic reviews on the same question reach different conclusions. The trust scores use heuristic weights that have not been validated against prospective outcome data.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can trust-weighted meta-meta-analysis quantify evidence erosion when quality, fragility, and bias are jointly considered? We developed TrustGate implementing trust-weighted pooling where each review receives a composite score from fragility index, GRADE certainty, bias indicators, and study overlap metrics. The trust gate down-weights low-trust reviews before meta-meta-analytic pooling, producing adjusted estimates and erosion diagnostics. Across 104 collections the trust-adjusted estimate diverged from naive pooling by median 0.12 standard deviations (95% CI 0.08 to 0.17), with 63.9 percent showing meaningful erosion. Red flag analysis identified 104 concerns with the most common being fragility below 3 and prediction intervals crossing the null. Trust-weighted synthesis could provide quality-adjusted pooling when multiple reviews reach different conclusions. The trust scores use heuristic weights not validated against prospective outcome data.
<!-- END-REWRITE -->

_Line range 24387-24461 in rewrite-workbook.txt_

---

## Entry 324 ([330/921]) — ctgov-registry-survival

<details><summary>Metadata</summary>

```
TITLE: CT.gov Registry Survival: Kaplan-Meier Analysis of Trial Registration to Completion
TYPE: methods  |  ESTIMAND: Median time from registration to results posting
DATA: ClinicalTrials.gov lifecycle data for registered trials
PATH: C:\Projects\ctgov-analyses/ctgov-registry-survival
```

</details>

### Original (frozen — do not edit)

```
What is the survival curve for clinical trials from registration through completion to results posting on ClinicalTrials.gov, and which design features predict timely completion? We applied Kaplan-Meier survival analysis to ClinicalTrials.gov lifecycle milestones, treating results posting as the event and ongoing or terminated trials as censored observations. The analysis computed median times from registration to start, start to completion, and completion to results posting, stratified by phase, sponsor class, and therapeutic area. Median time from registration to results posting was 6.8 years (95% CI 6.5 to 7.1) for phase 3 trials, with industry-sponsored trials posting 1.4 years faster than academic-sponsored trials on average. Completion-to-posting delay showed the widest variation, with 25 percent of completed trials still lacking results after 3 years despite FDAAA reporting requirements. Trial lifecycle survival analysis could identify structural bottlenecks in the evidence pipeline from registration through public availability. The analysis uses registry-reported dates which may not accurately reflect actual milestone timing for all trials.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What is the survival curve for clinical trials from registration through completion to results posting on ClinicalTrials.gov? We applied Kaplan-Meier analysis to lifecycle milestones, treating results posting as the event and ongoing or terminated trials as censored. The analysis computed median times from registration to start, start to completion, and completion to posting stratified by phase, sponsor, and area. Median time from registration to results posting was 6.8 years (95% CI 6.5 to 7.1) for phase 3 trials; industry sponsors posted 1.4 years faster than academic sponsors. Completion-to-posting delay showed widest variation with 25 percent of completed trials lacking results after 3 years. Lifecycle survival analysis could identify structural bottlenecks in the evidence pipeline from registration through availability. The analysis uses registry-reported dates which may not accurately reflect actual milestone timing.
<!-- END-REWRITE -->

_Line range 24462-24536 in rewrite-workbook.txt_

---

## Entry 325 ([331/921]) — surroNMA

<details><summary>Metadata</summary>

```
TITLE: SurroNMA: Surrogate-Validated Network Meta-Analysis for Oncology and Cardiology
TYPE: methods  |  ESTIMAND: Surrogate-calibrated treatment ranking
DATA: Multi-endpoint NMA datasets with surrogate and final outcome data
PATH: C:\Projects\surroNMA
```

</details>

### Original (frozen — do not edit)

```
Can surrogate endpoint validation be embedded within network meta-analysis to produce treatment rankings adjusted for differential surrogate validity across therapeutic comparisons? We developed SurroNMA implementing trial-level surrogate validation using Daniels and Hughes bivariate meta-analysis, surrogate threshold effect estimation, and network-level ranking adjustment based on validated versus unvalidated evidence contributions. The tool assesses surrogate validity for each comparison in the network and adjusts treatment rankings by down-weighting comparisons relying on inadequately validated surrogates. In oncology test networks the surrogate-adjusted ranking changed the top-ranked treatment in 2 of 5 scenarios compared with unadjusted NMA, with the largest ranking shifts occurring where progression-free survival was used as a surrogate for overall survival without adequate validation. Surrogate calibration reduced ranking uncertainty as measured by SUCRA confidence interval width by a mean of 12 percentage points across validated comparisons. Surrogate-validated NMA could improve the reliability of treatment rankings in therapeutic areas where regulatory approvals increasingly rely on surrogate endpoints. The approach requires per-comparison surrogate validation data that may not be available for all network edges.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can surrogate validation be embedded within NMA to produce rankings adjusted for differential surrogate validity? We developed SurroNMA implementing trial-level validation using Daniels and Hughes bivariate meta-analysis, surrogate threshold estimation, and network ranking adjustment based on validation status. The tool assesses surrogate validity per comparison and adjusts rankings by down-weighting inadequately validated evidence. In oncology networks surrogate adjustment changed the top-ranked treatment in 2 of 5 scenarios, with largest shifts where PFS substituted for OS without adequate validation. Surrogate calibration reduced ranking uncertainty by mean 12 percentage points across validated comparisons as measured by SUCRA CI width. Surrogate-validated NMA could improve ranking reliability where regulatory approvals rely on surrogate endpoints. The approach requires per-comparison validation data not available for all network edges.
<!-- END-REWRITE -->

_Line range 24537-24611 in rewrite-workbook.txt_

---

## Entry 326 ([332/921]) — Reversal-CAST

<details><summary>Metadata</summary>

```
TITLE: When Certainty Kills: The CAST Trial and 50,000 Deaths from Surrogate Endpoint Reliance
TYPE: clinical  |  ESTIMAND: Relative risk of death with anti-arrhythmic drugs vs placebo
DATA: CAST trial: 1,498 post-MI patients randomised to encainide, flecainide, or placebo (1989)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
How many patients died because anti-arrhythmic drugs were prescribed based on surrogate endpoint logic rather than randomised mortality evidence? The CAST trial randomised 1,498 post-myocardial infarction patients with premature ventricular contractions to encainide, flecainide, or placebo between 1987 and 1989. The trial tested the biological hypothesis that suppressing PVCs on electrocardiogram monitoring would prevent sudden cardiac death. The Data Safety Monitoring Board stopped the trial early when 56 deaths occurred in 755 drug-treated patients versus 22 deaths in 743 placebo patients, yielding a relative risk of death of 2.5 (95% CI 1.6 to 4.5, p less than 0.001). The drugs perfectly suppressed the surrogate endpoint while increasing the patient-important outcome by 150 percent. An estimated 50,000 Americans died from these drugs before the trial revealed that biological plausibility is not proof of clinical benefit. The CAST reversal cannot be detected by observational data alone because confounding by indication masks the true causal effect of treatment.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How many patients died because anti-arrhythmic drugs were prescribed based on surrogate endpoint logic rather than randomised evidence? The CAST trial randomised 1,498 post-MI patients with premature ventricular contractions to encainide, flecainide, or placebo. The trial tested whether suppressing PVCs on ECG monitoring would prevent sudden cardiac death. The DSMB stopped the trial when 56 deaths occurred in 755 drug patients versus 22 in 743 placebo patients, giving a relative risk of 2.5 (95% CI 1.6 to 4.5). The drugs perfectly suppressed the surrogate while increasing mortality by 150 percent. An estimated 50,000 Americans died from these drugs before the trial revealed that biological plausibility is not proof of benefit. This reversal cannot be detected by observational data alone because confounding by indication masks the true causal effect.
<!-- END-REWRITE -->

_Line range 24612-24686 in rewrite-workbook.txt_

---

## Entry 327 ([333/921]) — Reversal-HRT-WHI

<details><summary>Metadata</summary>

```
TITLE: The WHI Reversal: How Confounding Created a 40-Year Illusion of Cardiac Protection from Hormone Therapy
TYPE: clinical  |  ESTIMAND: Hazard ratio for cardiovascular events with HRT vs placebo
DATA: WHI trial: 16,608 postmenopausal women randomised to HRT or placebo (2002)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
How did four decades of observational evidence showing 50 percent cardiac protection from hormone replacement therapy collapse when a single randomised trial was conducted? The Women Health Initiative randomised 16,608 postmenopausal women to combined estrogen-progesterone or placebo, contradicting 40 years of cohort studies that had observed fewer heart attacks among HRT users. The trial measured cardiovascular events, stroke, breast cancer, and mortality as co-primary endpoints. HRT increased heart attacks by 29 percent, strokes by 41 percent, and breast cancer by 26 percent, reversing the direction of the observational evidence entirely. The explanation was confounding by indication: healthier women self-selected for HRT in observational studies, creating an illusion of cardiovascular protection that persisted across multiple cohorts and decades. Two million American women had been taking HRT specifically for heart protection based on evidence that was entirely confounded. The WHI reversal demonstrates that even consistent observational findings across multiple studies cannot establish causation when unmeasured confounders drive the association.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How did four decades of observational evidence showing cardiac protection from HRT collapse when a randomised trial was conducted? The WHI randomised 16,608 postmenopausal women to combined estrogen-progesterone or placebo, contradicting cohort studies observing fewer heart attacks among HRT users. The trial measured cardiovascular events, stroke, breast cancer, and mortality as co-primary endpoints. HRT increased heart attacks by 29 percent, strokes by 41 percent, and breast cancer by 26 percent, entirely reversing the observational evidence. Healthier women had self-selected for HRT in cohort studies, creating an illusion of cardiovascular protection that persisted across decades. Two million American women had been taking HRT for heart protection based on entirely confounded evidence. Even consistent observational findings across multiple studies cannot establish causation when unmeasured confounders drive the association.
<!-- END-REWRITE -->

_Line range 24687-24761 in rewrite-workbook.txt_

---

## Entry 328 ([334/921]) — Reversal-DECREASE

<details><summary>Metadata</summary>

```
TITLE: The DECREASE Fraud: 800,000 Deaths from Fabricated Evidence for Perioperative Beta-Blockers
TYPE: clinical  |  ESTIMAND: Estimated excess mortality from fraudulent guideline recommendations
DATA: 15 DECREASE trials by Don Poldermans; ESC/ACC perioperative guidelines (1999-2011)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
How many patients died because international guidelines recommended perioperative beta-blockers based on evidence that was later found to be fabricated by a single researcher? Don Poldermans published 15 DECREASE trials between 1999 and 2011 that formed the primary evidence base for European and American guidelines recommending beta-blockers before non-cardiac surgery. The trials reported consistent benefits of perioperative beta-blockade for preventing myocardial infarction, and guidelines graded the recommendation as strong with high certainty. Investigation in 2011 revealed fabricated patients, forged consent forms, and impossible data patterns across the trial series, leading to retraction and Poldermans dismissal from Erasmus Medical Centre. When the fraudulent studies were removed from meta-analyses, the pooled effect reversed direction, suggesting beta-blockers may have caused rather than prevented perioperative cardiac events. An estimated 800,000 patients died over a decade from following guidelines built on fabricated evidence from a single unreplicated source. Peer review and meta-analytic pooling cannot detect data fabrication, and concentration of evidence from one research group represents a critical vulnerability in the evidence ecosystem.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How many patients died because guidelines recommended perioperative beta-blockers based on fabricated evidence? Don Poldermans published 15 DECREASE trials forming the primary evidence for European and American guidelines recommending beta-blockers before non-cardiac surgery. Guidelines graded the recommendation as strong with high certainty based on consistent reported benefits. Investigation in 2011 revealed fabricated patients, forged consent, and impossible data, leading to retraction and dismissal from Erasmus Medical Centre. When fraudulent studies were removed from meta-analyses the pooled effect reversed, suggesting beta-blockers may have caused rather than prevented events. An estimated 800,000 patients died over a decade from following guidelines built on a single unreplicated source. Peer review and meta-analytic pooling cannot detect fabrication, and evidence concentration from one group is a critical vulnerability.
<!-- END-REWRITE -->

_Line range 24762-24836 in rewrite-workbook.txt_

---

## Entry 329 ([335/921]) — Reversal-Magnesium-ISIS4

<details><summary>Metadata</summary>

```
TITLE: Magnesium in Myocardial Infarction: When Seven Consistent Small Trials Were Contradicted by One Mega-Trial
TYPE: clinical  |  ESTIMAND: Odds ratio for mortality with IV magnesium vs control in MI
DATA: 7 small trials (1,301 patients) vs ISIS-4 mega-trial (58,050 patients)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
Can a meta-analysis of seven consistent small trials showing 56 percent mortality reduction be trusted when a subsequent mega-trial finds no effect whatsoever? Seven small randomised trials totalling 1,301 patients consistently showed that intravenous magnesium reduced mortality in myocardial infarction, producing a pooled odds ratio of 0.44 (95% CI 0.27 to 0.71). The ISIS-4 mega-trial then randomised 58,050 patients and found an odds ratio of 1.06 (95% CI 0.99 to 1.13), completely contradicting the prior meta-analysis. A Bayesian synthesis combining the prior evidence with the mega-trial likelihood produced a posterior odds ratio of approximately 0.93 (95% CI 0.79 to 1.09), reflecting genuine tension between the two evidence sources. The seven small trials likely shared common biases including publication bias and methodological limitations that inflated the treatment effect consistently across studies. This case demonstrates that consistency among small trials does not guarantee truth when all trials share the same systematic biases. The Bayesian posterior appropriately down-weights the prior when the mega-trial likelihood is strongly informative, but cannot determine which evidence source was biased.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a meta-analysis of seven consistent small trials be trusted when a mega-trial finds no effect? Seven small trials totalling 1,301 patients showed IV magnesium reduced MI mortality with a pooled odds ratio of 0.44 (95% CI 0.27 to 0.71). ISIS-4 then randomised 58,050 patients and found an odds ratio of 1.06 (95% CI 0.99 to 1.13), completely contradicting the meta-analysis. Bayesian synthesis produced a posterior of approximately 0.93 (95% CI 0.79 to 1.09), reflecting genuine tension between sources. The seven small trials likely shared common biases that inflated the effect consistently. Consistency among small trials does not guarantee truth when all share the same systematic biases. The Bayesian approach appropriately weights the evidence but cannot determine which source was biased.
<!-- END-REWRITE -->

_Line range 24837-24911 in rewrite-workbook.txt_

---

## Entry 330 ([336/921]) — Reversal-Aprotinin-BART

<details><summary>Metadata</summary>

```
TITLE: Aprotinin and the BART Trial: 15,000 Deaths from Ignoring Confounded Observational Evidence
TYPE: clinical  |  ESTIMAND: Relative risk of mortality with aprotinin in cardiac surgery
DATA: BART trial (2007) and prior observational and RCT evidence (1993-2007)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
How many patients died because aprotinin was used for 14 years in cardiac surgery based on confounded observational evidence while safety concerns were dismissed? Aprotinin was widely used from 1993 to reduce bleeding in cardiac surgery based on early studies suggesting efficacy, but observational evidence had severe confounding because sicker patients received the drug more often. The BART trial in 2007 demonstrated that aprotinin increased mortality compared to alternative antifibrinolytics, leading to withdrawal of the drug from the market. Prior randomised trials had been individually underpowered to detect the mortality signal because they were designed for bleeding outcomes rather than safety endpoints. An estimated 15,000 to 22,000 excess deaths occurred during the period when aprotinin was used despite accumulating safety concerns that were not adequately addressed. Early methodological scrutiny of the confounded observational evidence and adequately powered safety trials could have prevented a decade of avoidable harm. The case illustrates that trials powered for efficacy endpoints may systematically miss safety signals requiring much larger sample sizes.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How many patients died because aprotinin was used for 14 years based on confounded evidence while safety concerns were dismissed? Aprotinin was widely used from 1993 to reduce cardiac surgery bleeding, but observational evidence was confounded because sicker patients received the drug more often. The BART trial in 2007 showed aprotinin increased mortality, leading to market withdrawal. Prior RCTs were individually underpowered to detect the mortality signal because they were designed for bleeding outcomes. An estimated 15,000 to 22,000 excess deaths occurred during the period of use despite accumulating concerns. Early methodological scrutiny and adequately powered safety trials could have prevented a decade of avoidable harm. Trials powered for efficacy may systematically miss safety signals requiring much larger samples.
<!-- END-REWRITE -->

_Line range 24912-24986 in rewrite-workbook.txt_

---

## Entry 331 ([337/921]) — Reversal-Vioxx-VIGOR

<details><summary>Metadata</summary>

```
TITLE: Vioxx and the VIGOR Trial: Selective Reporting, Hidden Heart Attacks, and the Post-Hoc Data Cutoff
TYPE: clinical  |  ESTIMAND: Relative risk of myocardial infarction with rofecoxib vs naproxen
DATA: VIGOR trial: 8,076 patients with rheumatoid arthritis (Merck, 2000)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
Can post-hoc changes to analysis timepoints hide safety signals in randomised trial publications, and how many heart attacks resulted from selective reporting of the Vioxx data? The VIGOR trial randomised 8,076 rheumatoid arthritis patients to rofecoxib or naproxen, and the NEJM publication reported a fourfold increase in myocardial infarction with Vioxx. Three additional heart attacks occurred in the Vioxx group after the chosen data cutoff date, and Merck scientists were aware of these events before publication but selected the cutoff that excluded them. Including the post-cutoff events would have shown an even more alarming cardiovascular risk profile than the published fourfold increase. The NEJM later published an expression of concern calling the original paper inaccurate and incomplete, and Vioxx was withdrawn in 2004 after tens of thousands of patients suffered cardiovascular events. Selective reporting through post-hoc analysis timepoint selection represents a form of bias that cannot be detected from the published paper alone. Pre-registration of analysis plans and independent data monitoring could prevent post-hoc cutoff manipulation in future trials.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can post-hoc analysis timepoint changes hide safety signals, and how many heart attacks resulted from selective Vioxx reporting? The VIGOR trial randomised 8,076 RA patients to rofecoxib or naproxen, with the NEJM publication reporting a fourfold increase in MI with Vioxx. Three additional heart attacks in the Vioxx group after the data cutoff were known to Merck but excluded by the chosen analysis timepoint. Including post-cutoff events would have shown even more alarming cardiovascular risk than the published fourfold increase. The NEJM published an expression of concern calling the paper inaccurate and incomplete; Vioxx was withdrawn in 2004 after tens of thousands suffered events. Selective reporting through post-hoc timepoint selection cannot be detected from the published paper alone. Pre-registration of analysis plans could prevent cutoff manipulation in future trials.
<!-- END-REWRITE -->

_Line range 24987-25061 in rewrite-workbook.txt_

---

## Entry 332 ([338/921]) — Reversal-Rosiglitazone-RECORD

<details><summary>Metadata</summary>

```
TITLE: Rosiglitazone and RECORD: When a Safety Study Was Designed to Miss the Safety Signal
TYPE: clinical  |  ESTIMAND: Odds ratio for myocardial infarction with rosiglitazone vs control
DATA: RECORD trial (4,447 patients) and Nissen meta-analysis (2007)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
Can a cardiovascular safety trial be designed in a way that systematically underdetects the very events it is supposed to measure? Nissen meta-analysis showed rosiglitazone increased heart attacks with an odds ratio of 1.43 (95% CI 1.03 to 1.98), while the RECORD trial of 4,447 diabetes patients concluded rosiglitazone did not significantly increase cardiovascular risk. FDA re-analysis revealed that 35 percent of potential cardiovascular events in RECORD were not properly evaluated, with some events classified as non-cardiac when medical records suggested otherwise. The FDA estimated 83,000 excess heart attacks occurred between 1999 and 2007 from rosiglitazone prescribing based on incomplete safety evidence. Company adjudication of cardiovascular outcomes systematically underdetected the signal that independent meta-analysis had identified. A safety study designed and adjudicated by the company selling the drug has structural conflicts that can render the study incapable of detecting the harm it claims to measure. Independent outcome adjudication and pre-specified event definitions are essential safeguards when the sponsor has financial interest in a favourable safety profile.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a cardiovascular safety trial be designed to systematically underdetect the events it should measure? Nissen meta-analysis showed rosiglitazone increased heart attacks with odds ratio 1.43 (95% CI 1.03 to 1.98), while RECORD concluded no significant cardiovascular risk increase. FDA re-analysis revealed 35 percent of potential events in RECORD were not properly evaluated, with some classified as non-cardiac despite contradicting records. The FDA estimated 83,000 excess heart attacks between 1999 and 2007 from rosiglitazone prescribing. Company adjudication systematically underdetected the signal that independent meta-analysis had identified. A safety study designed and adjudicated by the sponsor has structural conflicts rendering it incapable of detecting harm. Independent adjudication and pre-specified event definitions are essential when sponsors have financial interest in favourable profiles.
<!-- END-REWRITE -->

_Line range 25062-25136 in rewrite-workbook.txt_

---

## Entry 333 ([339/921]) — Reversal-ACCORD

<details><summary>Metadata</summary>

```
TITLE: ACCORD: When Tighter Glucose Control Killed More Patients Than It Saved
TYPE: clinical  |  ESTIMAND: Hazard ratio for mortality with intensive vs standard glucose control
DATA: ACCORD trial: 10,251 type 2 diabetes patients (2008, stopped early for harm)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
Does tighter blood glucose control prevent cardiovascular death in type 2 diabetes, or can aggressive surrogate endpoint management cause more harm than benefit? The ACCORD trial randomised 10,251 type 2 diabetes patients to intensive glucose control targeting HbA1c below 6.0 percent or standard control targeting 7.0 to 7.9 percent. The trial was designed to test the biologically plausible hypothesis that lower glucose levels would reduce cardiovascular events. The Data Safety Monitoring Board stopped the intensive arm in February 2008 when 257 excess deaths were observed, representing a 22 percent increase in mortality with tighter glucose control. The surrogate endpoint improved as intended while the patient-important outcome worsened, exactly paralleling the CAST trial pattern of surrogate-outcome dissociation. Aggressive treatment of surrogate endpoints based on biological plausibility can cause harm when the surrogate mechanism does not capture the full pharmacological effect on mortality. The trial demonstrates that certainty based on mechanism alone is insufficient and that patient-important outcomes must be measured directly.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Does tighter glucose control prevent cardiovascular death, or can aggressive surrogate management cause harm? ACCORD randomised 10,251 type 2 diabetes patients to intensive control targeting HbA1c below 6.0 percent or standard control targeting 7.0 to 7.9 percent. The trial tested the biologically plausible hypothesis that lower glucose would reduce cardiovascular events. The DSMB stopped the intensive arm when 257 excess deaths occurred, a 22 percent increase in mortality with tighter control. The surrogate improved while mortality worsened, paralleling the CAST pattern of surrogate-outcome dissociation. Aggressive surrogate treatment based on biological plausibility can cause harm when the mechanism does not capture full pharmacological effects. Certainty based on mechanism alone is insufficient and patient-important outcomes must be measured directly.
<!-- END-REWRITE -->

_Line range 25137-25211 in rewrite-workbook.txt_

---

## Entry 334 ([340/921]) — Reversal-Knee-Arthroscopy

<details><summary>Metadata</summary>

```
TITLE: Knee Arthroscopy for Osteoarthritis: A $3 Billion Placebo Unmasked by Sham Surgery Trials
TYPE: clinical  |  ESTIMAND: Mean difference in pain and function scores between real and sham arthroscopy
DATA: Sham surgery RCTs for knee osteoarthritis arthroscopy (2002-2008)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
Can expert surgical experience distinguish real treatment effects from placebo when 700,000 patients per year undergo a procedure that sham surgery trials proved ineffective? Sham surgery randomised trials compared real knee arthroscopy for osteoarthritis against fake procedures where patients received skin incisions but no intra-articular intervention under the same anaesthetic conditions. The trials measured pain scores, functional outcomes, and patient satisfaction at multiple follow-up timepoints. Patients improved equally whether they received real arthroscopy or the sham procedure, with no statistically significant difference in any outcome measure across multiple independent trials. The findings achieved GRADE high certainty given well-designed RCTs with consistent results measuring direct patient-important outcomes. Prior to the sham trials, 700,000 Americans underwent knee arthroscopy annually at a cost of 3 billion dollars per year, and surgeons consistently reported observing patient improvement after the procedure. Uncontrolled clinical observation cannot detect placebo effects regardless of the observer expertise or consistency of reported improvement. Insurance coverage and guideline recommendations persisted for years after the sham trial evidence reached high certainty.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can expert surgical experience distinguish treatment effects from placebo when 700,000 patients annually undergo a procedure sham trials proved ineffective? Sham surgery trials compared real knee arthroscopy against fake procedures with skin incisions but no intra-articular intervention. The trials measured pain, function, and satisfaction at multiple timepoints. Patients improved equally with real or sham arthroscopy, with no significant difference in any outcome across independent trials. Findings achieved GRADE high certainty from well-designed RCTs with consistent direct outcomes. Before the trials, 700,000 Americans underwent arthroscopy annually at 3 billion dollars, and surgeons consistently reported observing improvement. Uncontrolled observation cannot detect placebo effects regardless of expertise, and guidelines persisted years after high-certainty evidence.
<!-- END-REWRITE -->

_Line range 25212-25286 in rewrite-workbook.txt_

---

## Entry 335 ([341/921]) — Reversal-Paroxetine-Study329

<details><summary>Metadata</summary>

```
TITLE: Study 329 and Paroxetine: How Ghost-Written Publications Manufactured Evidence for an Ineffective Drug
TYPE: clinical  |  ESTIMAND: Efficacy of paroxetine vs placebo for adolescent depression
DATA: Study 329 (GSK) and unpublished GSK trials; FDA regulatory data
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
How did a ghost-written publication create the illusion that paroxetine was effective for adolescent depression when the actual trial data showed it was no better than placebo and increased suicidal behaviour? Study 329, published in the Journal of the American Academy of Child and Adolescent Psychiatry, concluded paroxetine was generally well tolerated and effective for adolescent depression based on post-hoc outcome switching and selective reporting. The actual trial data showed paroxetine was not superior to placebo on any pre-specified primary endpoint, and the drug increased suicidal behaviour in treated adolescents. GSK conducted additional negative trials that were never published, creating a publication landscape where 94 percent of visible evidence appeared positive compared with 51 percent in the full FDA dataset. The publication was ghost-written by a medical communications company rather than the named academic authors, representing manufactured rather than passive publication bias. Thousands of adolescents were exposed to an ineffective and harmful drug based on a publication record that deliberately concealed negative findings. Funnel plots and statistical tests for publication bias cannot detect bias that is actively manufactured through ghost-writing and strategic non-publication.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How did a ghost-written publication create the illusion that paroxetine worked for adolescent depression when trial data showed otherwise? Study 329 concluded paroxetine was effective based on post-hoc outcome switching and selective reporting. Actual trial data showed paroxetine was not superior to placebo on any pre-specified endpoint and increased suicidal behaviour. GSK conducted additional negative trials never published, creating a landscape where 94 percent of visible evidence appeared positive versus 51 percent in full FDA data. The publication was ghost-written by a communications company rather than named academic authors, representing manufactured publication bias. Thousands of adolescents received an ineffective harmful drug based on deliberately concealed findings. Statistical tests for publication bias cannot detect bias actively manufactured through ghost-writing and strategic non-publication.
<!-- END-REWRITE -->

_Line range 25287-25361 in rewrite-workbook.txt_

---

## Entry 336 ([342/921]) — Reversal-Reboxetine

<details><summary>Metadata</summary>

```
TITLE: Reboxetine: The Antidepressant Where 74 Percent of Patient Data Was Hidden from Publication
TYPE: clinical  |  ESTIMAND: Treatment effect of reboxetine vs placebo when all trial data included
DATA: All clinical trials of reboxetine: published (26%) vs unpublished (74%)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
What happens to a drug efficacy conclusion when 74 percent of the patient data from clinical trials was never published and the visible literature represents only a curated subset? Published trials of the antidepressant reboxetine showed the drug was effective, leading to regulatory approval and widespread prescribing based on what appeared to be adequate evidence of benefit. When investigators obtained access to the complete trial database through freedom of information requests, they discovered that 74 percent of all patient data had never been published. Combining published and unpublished data revealed reboxetine was no better than placebo for depression and caused more side effects than other antidepressants, placing it at the bottom of the Cipriani 2018 network meta-analysis ranking. The published literature had created what investigators described as a complete fiction, where the visible evidence consistently supported efficacy because negative results were systematically withheld. Regulatory approval based on selective publication exposes patients to drugs that would not survive scrutiny if all data were available. Freedom of information requests remain the primary mechanism for accessing unpublished trial data that may contradict published conclusions.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What happens to efficacy conclusions when 74 percent of patient data was never published? Published trials of reboxetine showed the drug was effective, leading to regulatory approval and widespread prescribing. When investigators obtained the complete trial database through freedom of information requests, 74 percent of patient data had never been published. Combining all data revealed reboxetine was no better than placebo and caused more side effects, placing it at the bottom of the Cipriani 2018 network ranking. The published literature had created a complete fiction where visible evidence consistently supported efficacy because negative results were withheld. Regulatory approval based on selective publication exposes patients to drugs that would not survive full data scrutiny. Freedom of information requests remain the primary mechanism for accessing unpublished trial data.
<!-- END-REWRITE -->

_Line range 25362-25436 in rewrite-workbook.txt_

---

## Entry 337 ([343/921]) — Reversal-Albumin-SAFE

<details><summary>Metadata</summary>

```
TITLE: Albumin in Critical Care: When 28 Consistent Small Trials Showed 68 Percent Harm That a Mega-Trial Disproved
TYPE: clinical  |  ESTIMAND: Relative risk of mortality with albumin vs saline in critical illness
DATA: 28 Cochrane trials (1998 meta-analysis) vs SAFE trial (6,997 patients, 2004)
PATH: C:\Projects\Fatiha-Course
```

</details>

### Original (frozen — do not edit)

```
Can a meta-analysis of 28 consistent small trials showing 68 percent increased mortality be entirely wrong, and what does this reveal about the reliability of pooled evidence from underpowered studies? A 1998 Cochrane meta-analysis pooled 28 small trials and found albumin increased mortality in critically ill patients with a relative risk of 1.68, prompting headlines and near-banning by the NHS. The SAFE trial then randomised 6,997 patients and found albumin was equivalent to saline with a relative risk of 1.0, completely contradicting the prior meta-analysis. The 28 small trials shared common methodological limitations including tiny sample sizes, many under 50 patients, spanning different populations and decades, with heterogeneity near zero as an artifact of random variation rather than genuine consistency. Low I-squared in the prior meta-analysis was misleading because consistency among underpowered trials sharing the same biases does not indicate that the pooled effect is correct. A single large high-quality trial overturned the entire body of small-trial evidence because it was powered to detect the true effect. Consistency and low heterogeneity do not guarantee truth when all contributing studies share the same systematic limitations.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a meta-analysis of 28 consistent small trials showing 68 percent harm be entirely wrong? A 1998 Cochrane meta-analysis pooled 28 trials finding albumin increased mortality in critical illness with relative risk 1.68, prompting near-banning by the NHS. The SAFE trial randomised 6,997 patients and found albumin equivalent to saline with relative risk 1.0, completely contradicting the meta-analysis. The 28 trials shared limitations including tiny samples under 50 patients, spanning different populations, with near-zero heterogeneity as an artifact. Low I-squared was misleading because consistency among underpowered trials sharing biases does not indicate correct pooling. A single large trial overturned the entire small-trial evidence base. Consistency and low heterogeneity do not guarantee truth when studies share the same systematic limitations.
<!-- END-REWRITE -->

_Line range 25437-25510 in rewrite-workbook.txt_

---

## Entry 338 ([486/921]) — advanced-nma-pooling

<details><summary>Metadata</summary>

```
TITLE: Advanced NMA Pooling Toolkit with Bias Adjustment and Survival Extensions
TYPE: methods  |  ESTIMAND: Bias-adjusted treatment effect (log-odds)
DATA: A Python toolkit for advanced network meta-analysis with multilevel meta-regression, bias adjustment, and survival extensions validated against R benchmarks.
PATH: C:\Projects\advanced-nma-pooling
```

</details>

### Original (frozen — do not edit)

```
How can network meta-analysis accommodate individual patient data alongside aggregate data while adjusting for design-related biases across heterogeneous evidence sources? We developed a Python toolkit implementing multilevel network meta-regression, bias-adjusted models, and survival extensions for advanced evidence synthesis across different data types. The package provides frequentist and Bayesian backends with Stan integration, strict schema validation, config-driven pipelines, and validation against R netmeta and multinma benchmarks. In 18 network comparisons, the bias-adjusted model achieved mean absolute error of 0.003 log-odds units (95% CI 0.001 to 0.008) versus 0.021 for unadjusted pooling against R references. Design-stratified adjustment shifted the ranking probability for the top treatment by 11 percentage points relative to naive pooling, demonstrating clinically relevant sensitivity to design confounding. The toolkit enables reproducible advanced NMA workflows through command-line pipelines with model-card JSON outputs for transparent reporting and audit. One limitation is that Bayesian backends require Stan compilation, creating installation dependencies that may restrict accessibility for non-technical users.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25511-25582 in rewrite-workbook.txt_

---

## Entry 339 ([487/921]) — Pairwise70

<details><summary>Metadata</summary>

```
TITLE: MAFI: Meta-Analytic Fragility Index Across 501 Cochrane Pairwise Reviews
TYPE: methods  |  ESTIMAND: Median MAFI fragility index (IQR)
DATA: The median MAFI fragility score across 4,424 Cochrane meta-analyses is 0.31, classifying typical pairwise comparisons as moderately fragile.
PATH: C:\Projects\Pairwise70
```

</details>

### Original (frozen — do not edit)

```
What empirical patterns characterize meta-analytic fragility across a large corpus of Cochrane pairwise reviews? We extracted 501 meta-analysis datasets comprising over 50,000 randomized controlled trials from Cochrane reviews spanning CD000028 through CD016278, covering cardiology, oncology, psychiatry, surgery, and infectious diseases. The MAFI composite fragility index was computed for 4,424 meta-analyses from 473 reviews, combining decision fragility, statistical fragility, confidence interval fragility, effect magnitude, and heterogeneity components with weights of 30, 25, 20, 15, and 10 percent respectively. The median MAFI score was 0.31 (IQR 0.18 to 0.52), classifying the typical Cochrane comparison as moderately fragile, with 27 percent scoring below the robust threshold. Sensitivity analysis across 1,000 bootstrap iterations confirmed stable rankings with intraclass correlation exceeding 0.94 between resampled and original orderings. These results provide the first large-scale empirical benchmark for meta-analytic fragility in evidence-based medicine. A limitation is that the dataset captures a 2024 snapshot and excludes network meta-analyses, diagnostic accuracy reviews, and living updates.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25583-25655 in rewrite-workbook.txt_

---

## Entry 340 ([344/921]) — AlBurhan

<details><summary>Metadata</summary>

```
TITLE: Al-Burhan — Universal Evidence Orchestrator
TYPE: Meta-Analysis Pipeline | ESTIMAND: Multi-Engine Evidence Audit Quality
DATA: 19 engines, 40+ statistical methods, 128 tests
PATH: C:\AlBurhan
```

</details>

### Original (frozen — do not edit)

```
In patients with a specified condition, does current clinical evidence provide a robust basis for treatment compared with standard care? A multi-engine audit applies 19 specialized engines spanning random-effects meta-analysis, Bayesian hierarchical modelling, multiverse robustness testing, publication-bias detection, and causal sensitivity analysis. Reviewers utilized DerSimonian-Laird, REML, Paule-Mandel, and Sidik-Jonkman estimators alongside Knapp-Hartung correction, E-values, and Lan-DeMets alpha-spending trial sequential analysis. The pipeline produces frequentist confidence intervals, Bayesian credible intervals, posterior predictive intervals, and Savage-Dickey Bayes factors. Multiverse analysis classifies robustness across 10 specifications; GRADE certainty integrates five domains from upstream engines. Registry forensics applies terminal-digit analysis, GRIM consistency, Benford's law, and Shapiro-Wilk normality tests. Interpretation is limited by aggregate trial-level data and the scope of available pairwise comparisons.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25656-25731 in rewrite-workbook.txt_

---

## Entry 341 ([345/921]) — AfricaForecast

<details><summary>Metadata</summary>

```
TITLE: AfricaForecast: Causal Health Forecasting for 54 African Countries 2026-2036
TYPE: methods  |  ESTIMAND: Country-level health indicator forecast (BHVAR posterior mean and 95% credible interval)
DATA: WHO GHO, World Bank WDI, and IHME panel data for 54 African nations 2000-2025
PATH: C:\Models\AfricaForecast
```

</details>

### Original (frozen — do not edit)

```
Can causal Bayesian methods forecast health trajectories across all 54 African countries while identifying modifiable intervention targets? We assembled panel data from WHO, World Bank, and IHME covering mortality, vaccination, and health expenditure indicators for 54 African nations from 2000 to 2025. A Bayesian hierarchical vector autoregression with causal graph constraints was fitted using directed acyclic graphs encoding known public health pathways. Ten-year forecasts to 2036 yielded posterior mean coverage gains of 12 percentage points (95% credible interval 8 to 17) for DTP3 immunization under a sustained-investment counterfactual scenario. Counterfactual removal of health expenditure increases reversed 60 percent of projected mortality gains, confirming expenditure as the dominant modifiable driver. Ensemble forecasts combining BHVAR with gradient-boosted and ARIMA baselines reduced mean absolute error by 18 percent relative to any single model. The approach cannot account for political instability, conflict, or pandemic shocks not represented in historical data.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25732-25805 in rewrite-workbook.txt_

---

## Entry 342 ([346/921]) — EnrollmentOracle

<details><summary>Metadata</summary>

```
TITLE: EnrollmentOracle: ML Prediction of Clinical Trial Enrollment Speed from ClinicalTrials.gov Metadata
TYPE: methods  |  ESTIMAND: Predicted enrollment duration (months, 95% prediction interval)
DATA: ClinicalTrials.gov API v2, interventional trials 2010-2025
PATH: C:\Models\EnrollmentOracle
```

</details>

### Original (frozen — do not edit)

```
Can machine learning predict clinical trial enrollment speed from publicly available registry metadata before a trial opens? We extracted protocol features from ClinicalTrials.gov for interventional trials registered between 2010 and 2025 across all therapeutic areas. A gradient-boosted ensemble combining site count, eligibility complexity, phase, and therapeutic area predicted enrollment duration in months with calibrated prediction intervals. The model achieved a concordance index of 0.74 (95% CI 0.71 to 0.77) on a held-out test set stratified by sponsor type and geography. SHAP analysis identified number of sites and eligibility criterion count as the two most influential predictors, each contributing over 15 percent of feature importance. The interactive dashboard enables sponsors to explore enrollment projections and identify bottleneck features before trial launch. Predictions are limited to trial types represented in the training data and cannot anticipate regulatory or pandemic-related enrollment disruptions.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25806-25879 in rewrite-workbook.txt_

---

## Entry 343 ([347/921]) — HTNPipeline

<details><summary>Metadata</summary>

```
TITLE: HyperAtlas: A Bayesian Hypertension Prevalence Pipeline with WHO and World Bank Data Integration
TYPE: methods  |  ESTIMAND: National hypertension prevalence posterior mean and 95% credible interval
DATA: WHO Global Health Observatory, World Bank WDI, 54 indicator variables across 195 countries
PATH: C:\Models\HTNPipeline
```

</details>

### Original (frozen — do not edit)

```
Can a Bayesian hierarchical pipeline provide country-level hypertension prevalence estimates by integrating WHO and World Bank indicators? We harmonized 54 socioeconomic and health indicators from the WHO Global Health Observatory and World Bank for 195 countries from 2000 to 2024. A Gibbs sampler with conjugate priors estimated posterior distributions of national hypertension prevalence conditional on GDP, health expenditure, urbanization, and dietary risk factors. The pipeline produced prevalence estimates for 180 countries with a mean posterior width of 4.2 percentage points (95% credible interval 2.8 to 6.1) and cross-validated concordance of 0.81 against NCD-RisC benchmarks. Counterfactual analyses showed that a 10 percent increase in per-capita health expenditure was associated with a 1.3 percentage point reduction in hypertension prevalence. The interactive dashboard displays choropleth maps, counterfactual scenarios, and TruthCert-audited output bundles. Estimates depend on the completeness of WHO reporting and cannot replace direct population surveys in low-data settings.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25880-25953 in rewrite-workbook.txt_

---

## Entry 344 ([348/921]) — OutcomeSwitchDetector

<details><summary>Metadata</summary>

```
TITLE: OutcomeSwitchDetector: Automated Detection of Primary Outcome Switching in ClinicalTrials.gov Protocols
TYPE: methods  |  ESTIMAND: Outcome switching rate (proportion with 95% CI)
DATA: ClinicalTrials.gov API v2, protocol amendment histories
PATH: C:\Models\OutcomeSwitchDetector
```

</details>

### Original (frozen — do not edit)

```
Can automated text comparison detect primary outcome switching between clinical trial protocol versions registered on ClinicalTrials.gov? We harvested protocol amendment histories from ClinicalTrials.gov for interventional trials with at least two registered protocol versions. A diff engine with semantic endpoint parsing classified changes as additions, removals, or modifications of primary and secondary outcome measures. Across the analyzed cohort the outcome switching rate was 18.4 percent (95% CI 16.2 to 20.8) for primary endpoints, with oncology and cardiovascular trials showing the highest rates. Severity scoring weighted switches by clinical importance, with 6.1 percent classified as high-severity involving a change in the primary efficacy endpoint direction. The dashboard provides trial-level audit trails linking each detected switch to its protocol version timestamps. Detection is limited to changes captured in ClinicalTrials.gov structured fields and cannot identify unreported protocol amendments.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 25954-26027 in rewrite-workbook.txt_

---

## Entry 345 ([349/921]) — ProtocolEvolution

<details><summary>Metadata</summary>

```
TITLE: ProtocolEvolution: Mapping Temporal Patterns of Clinical Trial Protocol Amendments Across Therapeutic Areas
TYPE: methods  |  ESTIMAND: Amendment rate per trial-year (count with 95% CI)
DATA: ClinicalTrials.gov API v2, protocol version histories 2010-2025
PATH: C:\Models\ProtocolEvolution
```

</details>

### Original (frozen — do not edit)

```
How frequently do clinical trial protocols undergo amendments, and do amendment patterns differ systematically across therapeutic areas and trial phases? We extracted protocol version histories from ClinicalTrials.gov for interventional trials registered between 2010 and 2025 with at least one recorded amendment. A change classifier categorized amendments by type including eligibility modifications, endpoint changes, sample size adjustments, and administrative corrections. The median amendment rate was 2.3 per trial-year (95% CI 2.1 to 2.5), with phase III oncology trials showing the highest rate at 3.8 amendments per trial-year. Pattern detection identified eligibility broadening as the most common amendment type, occurring in 41 percent of amended trials within the first 12 months of enrollment. The interactive dashboard displays amendment timelines, category breakdowns, and cross-trial comparison heatmaps. Analysis is restricted to amendments recorded in ClinicalTrials.gov and underestimates true protocol change frequency.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 26028-26101 in rewrite-workbook.txt_

---

## Entry 346 ([350/921]) — TrialAtlas

<details><summary>Metadata</summary>

```
TITLE: TrialAtlas: A Network Visualization of Global Clinical Trial Connectivity Across Sites, Sponsors, and Conditions
TYPE: methods  |  ESTIMAND: Network centrality and community structure metrics
DATA: ClinicalTrials.gov API v2, trial-site-sponsor network for 400K+ trials
PATH: C:\Models\TrialAtlas
```

</details>

### Original (frozen — do not edit)

```
Can network analysis reveal the hidden connectivity structure linking clinical trial sites, sponsors, and therapeutic conditions across the global registry? We constructed a tripartite network from ClinicalTrials.gov linking trial sites, sponsors, and medical conditions for over 400,000 registered interventional studies. Community detection using Louvain modularity identified 23 distinct research clusters, with the largest cardiovascular-metabolic cluster spanning 47 countries and 2,800 unique sites. Network centrality analysis revealed that the top 50 sites by betweenness centrality participated in 12 percent of all registered trials, suggesting concentration risk in the global trial infrastructure. Geographic analysis identified 31 countries with no site appearing in any detected community, indicating research isolation. The interactive dashboard provides force-directed network visualization, community exploration, and site-level connectivity metrics. The analysis captures only ClinicalTrials.gov-registered trials and may underrepresent activity in countries that primarily use other registries.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 26102-26175 in rewrite-workbook.txt_

---

## Entry 347 ([351/921]) — E156

<details><summary>Metadata</summary>

```
TITLE: E156: A Compact Evidence-Synthesis Micro-Paper Format for Standardized Reporting of Meta-Analytic Results
TYPE: methods  |  ESTIMAND: Format compliance rate (proportion meeting 7-sentence 156-word constraint)
DATA: 339 meta-analysis projects converted to E156 format
PATH: C:\E156
```

</details>

### Original (frozen — do not edit)

```
Can a fixed 7-sentence, 156-word micro-paper format standardize the reporting of meta-analytic results while preserving essential information for clinical decision-making? We developed the E156 specification requiring exactly seven sentences covering question, dataset, method, result, robustness, interpretation, and limitation within a maximum of 156 words. The format was applied to 339 meta-analysis projects spanning pairwise, network, diagnostic accuracy, and prevalence synthesis types. All 339 entries achieved full compliance with the 7-sentence constraint, and mean word count was 152.4 (range 138 to 156) demonstrating the format accommodates diverse study designs. An interactive library dashboard and batch validation pipeline enforce compliance automatically, with scripts for workbook management, GitHub deployment, and protocol timestamping. The E156 format enables rapid editorial triage, systematic comparison across evidence syntheses, and machine-readable extraction of key results. The format cannot capture nuanced subgroup analyses or complex network geometries that require extended narrative.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 26176-26249 in rewrite-workbook.txt_

---

## Entry 348 ([352/921]) — NICECardiology

<details><summary>Metadata</summary>

```
TITLE: NICE Cardiology Guidance Under the Microscope: A Data-Driven Statistical Critique
TYPE: methods  |  ESTIMAND: HR
DATA: 20 Phase 3 SGLT2i trials (28,553 patients), 7 lipid trials (67,254 patients), 5 triangulation sources
PATH: C:\NICECardiology
GITHUB: https://github.com/mahmood726-cyber/nice-cardiology-guidance
PAGES: https://mahmood726-cyber.github.io/nice-cardiology-guidance/
```

</details>

### Original (frozen — do not edit)

```
Can client-side meta-analytic computation expose systematic evidence-adoption gaps in national clinical guidelines? We analysed NICE heart failure and acute coronary syndrome guidelines against 20 completed Phase 3 SGLT2 inhibitor trials enrolling 28,553 patients and 7 post-ACS lipid trials enrolling 67,254 patients, cross-referencing CT.gov registry data, EMA/FDA/WHO regulatory timelines, NHS prescribing statistics, and six international guideline bodies. Forty statistical methods including DerSimonian-Laird pooling, trial sequential analysis, Monte Carlo simulation, Markov QALY modelling, Bayesian model averaging, persistent homology, and E-values were computed entirely client-side in 10,463 lines of dependency-free JavaScript. The pooled SGLT2i class-effect HR was 0.79 (95% CI 0.74-0.84, I-squared 28%) across eight trials with Monte Carlo reversal probability below 0.1 percent; NICE ranked last of six guideline bodies in adoption timing. Fourteen NYT-style canvas charts and on-demand WebR cross-validation with R metafor provide full computational reproducibility. The analysis cannot account for unpublished NICE cost-effectiveness deliberations.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 26250-26328 in rewrite-workbook.txt_

---

## Entry 349 ([353/921]) — TrialDiversityAtlas

<details><summary>Metadata</summary>

```
TITLE: TrialDiversityAtlas: Quantifying Demographic Representation Gaps in Global Clinical Trials
TYPE: methods  |  ESTIMAND: Representation Disparity Index (RDI)
DATA: 100,000 ClinicalTrials.gov results + IHME Global Burden of Disease demographics
PATH: C:\Users\user\projects\TrialDiversityAtlas
```

</details>

### Original (frozen — do not edit)

```
Can we quantify the systematic underrepresentation of demographic groups in clinical trials compared to real-world disease burden? We matched demographic baseline characteristics from 100,000 completed trials on ClinicalTrials.gov against age and sex demographics from the IHME Global Burden of Disease dataset across 20 therapeutic areas. TrialDiversityAtlas computes the Representation Disparity Index (RDI), comparing the enrolled demographic proportions to expected real-world prevalence. Across the cardiovascular and oncology cohorts, female participation was 14 percentage points (95% CI 11-17) lower than expected disease burden, while older adults (>65 years) were underrepresented by 22 percentage points. The interactive dashboard allows users to visualize demographic gaps, generate disparity heatmaps by sponsor, and perform counterfactual sample size reweighting. This reveals that unadjusted meta-analyses systematically over-index on young, male populations, potentially misestimating treatment efficacy for broader demographic groups. The analysis is limited by the frequent omission of detailed race and ethnicity data in historical clinical trial reporting.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 26329-26402 in rewrite-workbook.txt_

---

## Entry 350 ([354/921]) — ProtocolEvolutionDynamics

<details><summary>Metadata</summary>

```
TITLE: Protocol Evolution Dynamics: Tracking Adaptations in ClinicalTrials.gov
TYPE: novel  |  ESTIMAND: Trial Adaptation Frequency (TAF)
DATA: ClinicalTrials.gov API v2 historical data
PATH: C:\Users\user\Projects\ctgov-protocol-evolution
```

</details>

### Original (frozen — do not edit)

```
Clinical trial protocols dynamically adapt over their lifecycle to resolve operational and scientific challenges. We analyzed 10,000 multi-disease trials from ClinicalTrials.gov using Benford's Law to detect reporting anomalies in enrollment data. The analytical engine implements unsupervised K-means clustering to identify trial archetypes based on enrollment size, study duration, and outcome density. We computed the Gini coefficient across a diversified research landscape including oncology, diabetes, and neurology to measure structural enrollment inequality. Statistical provenance is secured via TruthCert cryptographic hashing and deterministic Numpy-only topological processing to ensure absolute reproducibility. These analytics are rendered in an interactive dashboard providing real-time insights into study execution fidelity and data integrity. This project establishes a novel, multi-dimensional framework for monitoring reporting anomalies and trial species distribution in global clinical research.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
<!-- END-REWRITE -->

_Line range 26403-26476 in rewrite-workbook.txt_

---

